Targeting hypoxia and angiogenesis through HIF-1α inhibition Journal Article
| Authors: | Díaz-González, J. A.; Russell, J.; Rouzaut, A.; Gil-Bazo, I.; Montuenga, L. |
| Article Title: | Targeting hypoxia and angiogenesis through HIF-1α inhibition |
| Abstract: | Hypoxia is an important phenomenon in the tumor microenvironment. Hypoxic tumors are more aggressive and resistant to anti-neoplastic treatments. HIF-1α plays a major role in the response of tumors to hypoxia, and it is mainly responsible for the "angiogenic switch". HIF-1α contributes to tumor aggressiveness, invasiveness, and resistance to radiotherapy and chemotherapy. Targeting HIF-1α is an attractive strategy, with the potential for disrupting multiple pathways crucial for tumor growth. We review recent findings on the potential efficacy of small molecules to downregulate HIF-1α. These promising drugs inhibit HIF-1α synthesis or transcriptional activity by blocking a variety of steps in several different signaling pathways. Blocking HIF-1α activity should not only downregulate tumor angiogenesis, but also interfere with glycolytic metabolism and tumor cell growth. This strategy could also improve the efficiency of established tumor therapies. ©2005 Landes Bioscience. |
| Keywords: | signal transduction; cancer chemotherapy; unclassified drug; clinical trial; review; nonhuman; cancer radiotherapy; topotecan; positron emission tomography; antineoplastic agent; protein function; metabolism; gene targeting; models, biological; transcription initiation; etoposide; 7 ethyl 10 hydroxycamptothecin; peptide; molecular imaging; angiogenesis; neovascularization, pathologic; cancer therapy; irinotecan; temsirolimus; hypoxia; cancer invasion; protein synthesis; protein farnesyltransferase inhibitor; semaxanib; tipifarnib; microtubule assembly; targeted therapy; down regulation; cell hypoxia; microenvironment; tumor growth; dna topoisomerase inhibitor; everolimus; rapamycin; glycolysis; 2 morpholino 8 phenylchromone; 2 methoxyestradiol; molecular therapy; hypoxia inducible factor 1; hypoxia-inducible factor 1; hif-1α; ap 23573; lonafarnib; 17 allylamino 17 demethoxygeldanamycin; 17 dimethylaminoethylamino 17 demethoxygeldanamycin; molecular inhibitors; 1 benzyl 3 (5 hydroxymethyl 2 furyl)indazole; 9 beta dextro arabinofurasonyl 2 fluoroadenine; abt 578; ap 23481; chetomin; px 478 |
| Journal Title: | Cancer Biology and Therapy |
| Volume: | 4 |
| Issue: | 10 |
| ISSN: | 1538-4047 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2005-10-01 |
| Start Page: | 1055 |
| End Page: | 1062 |
| Language: | English |
| PUBMED: | 16294030 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 24" - "Export Date: 24 October 2012" - "Source: Scopus" |
Citation Impact
MSK Authors
Related MSK Work